We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GMED - GenoMed Inc.
GMED 71.07+0.5%Jul 12 4:00 PM EDT

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: jmhollen9/1/2005 3:13:57 PM
  Read Replies (1) of 347
GenoMed Scores 13th Victory Treating Neuroinvasive West Nile Virus in Humans

Contact: David Moskowitz MD GenoMed, Inc. tel. 314-983-9933

ST. LOUIS—September 1, 2005--GenoMed Inc.-- ("the Company" or "GenoMed") (National Quotation Bureau's Pink Sheets Symbol: GMED) a St. Louis, Missouri-based Next Generation Disease Management company, announced today that it successfully treated its thirteenth patient with presumed West Nile virus encephalitis.

The patient is a previously healthy man from Aberdeen, South Dakota who developed fever and headache and was diagnosed by his physician as having West Nile virus on Monday of this week. South Dakota has about 50 times higher incidence of West Nile virus this summer than California.

The patient found GenoMed on the Internet, and within 2 hours his physician had started him on an angiotensin II receptor blocker, GenoMed's patent-pending approach to most viral diseases, including West Nile virus. The patient's headache intensified over the next 24 hours, requiring a visit to the Emergency Room, where he was offered a spinal tap, but not hospitalized. The patient went home and slept most of the following day. He awoke in the afternoon without a high fever or neck stiffness any more.

David Moskowitz MD, FACP, GenoMed's Chief Medical Officer and CEO, commented, "This patient demonstrated an extremely rapid resolution of his symptoms, several days faster than expected. Our treatment failed to prevent progression to meningitis, which we've seen before, but it did result in an extremely rapid recovery thereafter, within the next 24 hours. The patient could just as easily have progressed to full-blown coma, which was a concern the night he went to the ER. Normally it takes 3-6 days to recover from West Nile virus meningo-encephalitis. This patient's total recovery time was a bit under 48 hours, and under 24 hours from his worst symptoms of neck stiffness or meningitis."

During the past three summers, GenoMed has treated 16 patients, of whom this patient represents the 13th treatment success (81%). GenoMed has had a 50% treatment success rate in birds, and is eager to treat horses, also.

To enroll in GenoMed's free clinical trial, which uses already existing, safe medication present in every drug store and hospital, just go to and click on the link for the West Nile virus trial.

About GenoMed

GenoMed has found what it believes to be the "master" disease gene, and has already been able to prevent kidney failure due to diabetes and hypertension in whites, blacks and Hispanics; dramatically delay the progression of terminal emphysema; and begin to see success in treating autoimmune diseases, West Nile virus encephalitis, and cancer. GenoMed's broad-spectrum anti-viral approach was specifically mentioned in BioShield II, recently introduced in the US Senate (see Section 2151 of Senate bill S. 975). GenoMed has recently found several thousand genes for the top six solid cancers in Caucasians--breast, colon, lung, ovarian, pancreatic, and prostate--and is currently offering its Healthchip(r) for early diagnosis of cancer on a research basis.

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext